|
1
|
Ahmed GM, Abed MN and Alassaf FA: Impact
of calcium channel blockers and angiotensin receptor blockers on
hematological parameters in type 2 diabetic patients. Naunyn
Schmiedebergs Arch Pharmacol. 397:1817–1828. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Liu X, Xu Y, An M and Zeng Q: The risk
factors for diabetic peripheral neuropathy: A meta-analysis. PLoS
One. 14(e0212574)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
González P, Lozano P, Ros G and Solano F:
Hyperglycemia and oxidative stress: An integral, updated and
critical overview of their metabolic interconnections. Int J Mol
Sci. 24(9352)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Al-dabbagh BM, Abed MN, Mahmood NM,
Alassaf FA, Jasim MH, Alfahad MA and Thanoon IAJ:
Anti-inflammatory, antioxidant and hepatoprotective potential of
milk thistle in albino rats. Lat Am J Pharm. 41:1832–1841.
2022.
|
|
5
|
Hadid KA, Alassaf FA and Abed MN:
Mechanisms and linkage of insulin signaling, resistance, and
inflammation. Iraqi J Pharm. 21:1–8. 2024.
|
|
6
|
Lin Q, Li K, Chen Y, Xie J, Wu C, Cui C
and Deng B: Oxidative stress in diabetic peripheral neuropathy:
Pathway and mechanism-based treatment. Mol Neurobiol. 60:4574–4594.
2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Griggs RB, Donahue RR, Adkins BG, Anderson
KL, Thibault O and Taylor BK: Pioglitazone inhibits the development
of hyperalgesia and sensitization of spinal nociresponsive neurons
in type 2 diabetes. J Pain. 17:359–373. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
García-Casares N, González-González G, de
la Cruz-Cosme C, Garzón-Maldonado FJ, de Rojas-Leal C, Ariza MJ,
Narváez M, Barbancho MÁ, García-Arnés JA and Tinahones FJ: Effects
of GLP-1 receptor agonists on neurological complications of
diabetes. Rev Endocr Metab Disord. 24:655–672. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Han W, Li Y, Cheng J, Zhang J, Chen D,
Fang M, Xiang G, Wu Y, Zhang H, Xu K, et al: Sitagliptin improves
functional recovery via GLP-1R-induced anti-apoptosis and
facilitation of axonal regeneration after spinal cord injury. J
Cell Mol Med. 24:8687–8702. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Maeda-Gutiérrez V, Galván-Tejada CE, Cruz
M, Valladares-Salgado A, Galván-Tejada JI, Gamboa-Rosales H,
García-Hernández A, Luna-García H, Gonzalez-Curiel I and
Martínez-Acuña M: Distal symmetric polyneuropathy identification in
type 2 diabetes subjects: A random forest approach. Healthcare
(Basel). 9(138)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Oh J: Clinical spectrum and diagnosis of
diabetic neuropathies. Korean J Intern Med. 35:1059–1069.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sharma JK, Rohatgi A and Sharma D:
Diabetic autonomic neuropathy: A clinical update. J R Coll
Physicians Edinb. 50:269–273. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bell DSH: Diabetic mononeuropathies and
diabetic amyotrophy. Diabetes Ther. 13:1715–1722. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ahmed GM, Abed MN and Alassaf FA: The
diabetic-anemia nexus: Implications for clinical practice. Mil Med
Sci Lett. 92:1–11. 2023.
|
|
15
|
Bhatti JS, Sehrawat A, Mishra J, Sidhu IS,
Navik U, Khullar N, Kumar S, Bhatti GK and Reddy PH: Oxidative
stress in the pathophysiology of type 2 diabetes and related
complications: Current therapeutics strategies and future
perspectives. Free Radic Biol Med. 184:114–134. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mosquera-Sulbarán JA and Hernández-Fonseca
JP: Advanced glycation end products in diabetes. In: Patel VB,
Preedy VR (eds) Biomarkers in Diabetes. Biomarkers in Disease:
Methods, Discoveries and Applications. Springer, Cham, pp171-194,
2023.
|
|
17
|
Abed MN, Alassaf FA, Jasim MHM, Alfahad M
and Qazzaz ME: Comparison of antioxidant effects of the proton
pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole,
pantoprazole, and rabeprazole. Pharmacology. 105:645–651.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Alfahad M, Qazzaz ME, Abed MN, Alassaf FA
and Jasim MHM: Comparison of anti-oxidant activity of different
brands of esomeprazole available in Iraqi pharmacies. Syst Rev
Pharm. 11:330–33. 2020.
|
|
19
|
Dilworth L, Stennett D, Facey A, Omoruyi
F, Mohansingh S and Omoruyi FO: Diabetes and the associated
complications: The role of antioxidants in diabetes therapy and
care. Biomed Pharmacother. 181(117641)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ganjifrockwala FA, Joseph JT and George G:
Decreased total antioxidant levels and increased oxidative stress
in South African type 2 diabetes mellitus patients. J Endocrinol
Metab Diabetes South Africa. 22:21–25. 2017.
|
|
21
|
Pang L, Lian X, Liu H, Zhang Y, Li Q, Cai
Y, Ma H and Yu X: Understanding diabetic neuropathy: Focus on
oxidative stress. Oxid Med Cell Longev.
2020(9524635)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zampieri M, Bacalini MG, Barchetta I,
Scalea S, Cimini FA, Bertoccini L, Tagliatesta S, De Matteis G,
Zardo G, Cavallo MG and Reale A: Increased PARylation impacts the
DNA methylation process in type 2 diabetes mellitus. Clin
Epigenetics. 13(114)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chung SSM, Ho ECM, Lam KSL and Chung SK:
Contribution of polyol pathway to diabetes-induced oxidative
stress. J Am Soc Nephrol. 14 (8 Suppl 3):S233–S236. 2003.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lv Y, Yao X, Li X, Ouyang Y, Fan C and
Qian Y: Cell metabolism pathways involved in the pathophysiological
changes of diabetic peripheral neuropathy. Neural Regen Res.
19:598–605. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gugliucci A: Formation of
fructose-mediated advanced glycation end products and their roles
in metabolic and inflammatory diseases. Adv Nutr. 8:54–62.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rendell MS: The time to develop treatments
for diabetic neuropathy. Expert Opin Investig Drugs. 30:119–130.
2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Niimi N, Yako H, Takaku S, Chung SK and
Sango K: Aldose reductase and the polyol pathway in schwann cells:
Old and new problems. Int J Mol Sci. 22(1031)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Brownlee M: Biochemistry and molecular
cell biology of diabetic complications. Nature. 414:813–820.
2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nagel AK and Ball LE: Intracellular
protein O-GlcNAc modification integrates nutrient status with
transcriptional and metabolic regulation. Adv Cancer Res.
126:137–166. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Paneque A, Fortus H, Zheng J, Werlen G and
Jacinto E: The hexosamine biosynthesis pathway: Regulation and
function. Genes (Basel). 14(933)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Nelson ZM, Leonard GD and Fehl C: Tools
for investigating O-GlcNAc in signaling and other fundamental
biological pathways. J Biol Chem. 300(105615)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Alasaf FA, Jasim MHM, Alfahad M, Qazzaz
ME, Abed MN and Thanoo IAJ: Effects of bee propolis on FBG, HbA1c,
and insulin resistance in healthy volunteers. Turkish J Pharm Sci.
18:405–409. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Buse MG, Robinson KA, Gettys TW, McMahon
EG and Gulve EA: Increased activity of the hexosamine synthesis
pathway in muscles of insulin-resistant ob/ob mice. Am J Physiol.
272:E1080–E1088. 1997.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Papachristou S, Pafili K and Papanas N:
Skin AGEs and diabetic neuropathy. BMC Endocr Disord.
21(28)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sugimoto K, Yasujima M and Yagihashi S:
Role of advanced glycation end products in diabetic neuropathy.
Curr Pharm Des. 14:953–961. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jasim MHM, Alfahad M, Al-Dabbagh BM,
Alassaf FA, Abed MN and Mustafa YF: Synthesis, characterization,
ADME study and in-vitro anti-inflammatory activity of aspirin amino
acid conjugates. Pharm Chem J. 57:243–249. 2023.
|
|
37
|
Kim J and Lee J: Role of obesity-induced
inflammation in the development of insulin resistance and type 2
diabetes: History of the research and remaining questions. Ann
Pediatr Endocrinol Metab. 26:1–13. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kolczynska K, Loza-Valdes A, Hawro I and
Sumara G: Diacylglycerol-evoked activation of PKC and PKD isoforms
in regulation of glucose and lipid metabolism: A review. Lipids
Health Dis. 19(113)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kim H, Sasaki T, Maeda K, Koya D,
Kashiwagi A and Yasuda H: Protein kinase Cbeta selective inhibitor
LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP
level of dorsal root ganglion neurons. Diabetes. 52:2102–2109.
2003.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Oyenihi AB, Ayeleso AO, Mukwevho E and
Masola B: Antioxidant strategies in the management of diabetic
neuropathy. Biomed Res Int. 2015(515042)2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Arruri VK, Gundu C, Khan I, Khatri DK and
Singh SB: PARP overactivation in neurological disorders. Mol Biol
Rep. 48:2833–2841. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Brady PN, Goel A and Johnson MA:
Poly(ADP-ribose) polymerases in host-pathogen interactions,
inflammation, and immunity. Microbiol Mol Biol Rev. 83:e00038–18.
2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yuan P, Song F, Zhu P, Fan K, Liao Q,
Huang L and Liu Z: Poly (ADP-ribose) polymerase 1-mediated
defective mitophagy contributes to painful diabetic neuropathy in
the db/db model. J Neurochem. 162:276–289. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kumar A and Mittal R: Nrf2: A potential
therapeutic target for diabetic neuropathy. Inflammopharmacology.
25:393–402. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gawli K and Bojja KS: Molecules and
targets of antidiabetic interest. Phytomedicine Plus.
4(100506)2024.
|
|
46
|
Alnaser RI, Alassaf FA and Abed MN:
Adulteration of hypoglycemic products: The silent threat. Rom J Med
Pract. 18:157–160. 2023.
|
|
47
|
Abdollahi E, Keyhanfar F, Delbandi AA,
Falak R, Hajimiresmaiel SJ and Shafiei M: Dapagliflozin exerts
anti-inflammatory effects via inhibition of LPS-induced TLR-4
overexpression and NF-κB activation in human endothelial cells and
differentiated macrophages. Eur J Pharmacol.
918(174715)2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mehdi SF, Pusapati S, Anwar MS, Lohana D,
Kumar P, Nandula SA, Nawaz FK, Tracey K, Yang H, LeRoith D, et al:
Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent.
Front Immunol. 14(1148209)2023.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Singh RK, Gupta B, Tripathi K and Singh
SK: Anti oxidant potential of metformin and pioglitazone in type 2
diabetes mellitus: Beyond their anti glycemic effect. Diabetes
Metab Syndr. 10:102–104. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Rena G, Hardie DG and Pearson ER: The
mechanisms of action of metformin. Diabetologia. 60:1577–1585.
2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Fontaine E: Metformin-induced
mitochondrial complex I Inhibition: Facts, uncertainties, and
consequences. Front Endocrinol (Lausanne). 9(753)2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Martín-Rodríguez S, de Pablos-Velasco P
and Calbet JAL: Mitochondrial complex I inhibition by metformin:
Drug-exercise interactions. Trends Endocrinol Metab. 31:269–271.
2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Cameron AR, Logie L, Patel K, Erhardt S,
Bacon S, Middleton P, Harthill J, Forteath C, Coats JT, Kerr C, et
al: Metformin selectively targets redox control of complex I energy
transduction. Redox Biol. 14:187–197. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Carvalho C, Correia S, Santos MS, Seiça R,
Oliveira CR and Moreira PI: Metformin promotes isolated rat liver
mitochondria impairment. Mol Cell Biochem. 308:75–83.
2008.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wei J, Wei Y, Huang M, Wang P and Jia S:
Is metformin a possible treatment for diabetic neuropathy? J
Diabetes. 14:658–669. 2022.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Lós DB, Oliveira WH, Duarte-Silva E,
Sougey WWD, Freitas EDSR, de Oliveira AGV, Braga CF, França MER,
Araújo SMDR, Rodrigues GB, et al: Preventive role of metformin on
peripheral neuropathy induced by diabetes. Int Immunopharmacol.
74(105672)2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Alcántara Montero A, Goicoechea García C,
Pacheco de Vasconcelos SR and Alvarado PMH: Potential benefits of
metformin in the treatment of chronic pain. Neurol Perspect.
2:107–109. 2022.
|
|
58
|
Kim SH, Park TS and Jin HY: Metformin
preserves peripheral nerve damage with comparable effects to alpha
lipoic acid in streptozotocin/high-fat diet induced diabetic rats.
Diabetes Metab J. 44:842–853. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Kakhki FSH, Asghari A, Bardaghi Z,
Anaeigoudari A, Beheshti F, Salmani H and Hosseini M: The
antidiabetic drug metformin attenuated depressive and anxiety-like
behaviors and oxidative stress in the brain in a rodent model of
inflammation induced by lipopolysaccharide in male rats. Endocr
Metab Immune Disord Drug Targets. 24:1525–1537. 2024.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Yang R, Yu H, Wu J, Chen H, Wang M, Wang
S, Qin X, Wu T, Wu Y and Hu Y: Metformin treatment and risk of
diabetic peripheral neuropathy in patients with type 2 diabetes
mellitus in Beijing, China. Front Endocrinol (Lausanne).
14(1082720)2023.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Alvarez M, Sierra OR, Saavedra G and
Moreno S: Vitamin B12 deficiency and diabetic neuropathy in
patients taking metformin: A cross-sectional study. Endocr Connect.
8:1324–1329. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Ragazzi E, Burlina S, Cosma C, Chilelli
NC, Lapolla A and Sartore G: Anti-diabetic combination therapy with
pioglitazone or glimepiride added to metformin on the AGE-RAGE
axis: A randomized prospective study. Front Endocrinol (Lausanne).
14(1163554)2023.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Krauss H, Koźlik J, Grzymisławski M,
Sosnowski P, Mikrut K, Piatek J and Paluszak J: The influence of
glimepiride on the oxidative state of rats with
streptozotocin-induced hyperglycemia. Med Sci Monit. 9:BR389–BR393.
2003.PubMed/NCBI
|
|
64
|
O'Brien RC, Luo M, Balazs N and Mercuri J:
In vitro and in vivo antioxidant properties of gliclazide. J
Diabetes Complications. 14:201–206. 2000.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Choi SW and Ho CK: Antioxidant properties
of drugs used in type 2 diabetes management: Could they contribute
to, confound or conceal effects of antioxidant therapy? Redox Rep.
23:1–24. 2018.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Qiang X, Satoh J, Sagara M, Fukuzawa M,
Masuda T, Miyaguchi S, Takahashi K and Toyota T: Gliclazide
inhibits diabetic neuropathy irrespective of blood glucose levels
in streptozotocin-induced diabetic rats. Metabolism. 47:977–981.
1998.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Kou J, Klorig DC and Bloomquist JR:
Potentiating effect of the ATP-sensitive potassium channel blocker
glibenclamide on complex I inhibitor neurotoxicity in vitro and in
vivo. Neurotoxicology. 27:826–834. 2006.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Hwang J, Kleinhenz DJ, Rupnow HL, Campbell
AG, Thulé PM, Sutliff RL and Hart CM: The PPARgamma ligand,
rosiglitazone, reduces vascular oxidative stress and NADPH oxidase
expression in diabetic mice. Vascul Pharmacol. 46:456–462.
2007.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Alhowail A, Alsikhan R, Alsaud M,
Aldubayan M and Rabbani SI: Protective effects of pioglitazone on
cognitive impairment and the underlying mechanisms: A review of
literature. Drug Des Devel Ther. 16:2919–2931. 2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Al-Muzafar HM, Alshehri FS and Amin KA:
The role of pioglitazone in antioxidant, anti-inflammatory, and
insulin sensitivity in a high fat-carbohydrate diet-induced rat
model of insulin resistance. Braz J Med Biol Res.
54(e10782)2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Qiang X, Satoh J, Sagara M, Fukuzawa M,
Masuda T, Sakata Y, Muto G, Muto Y, Takahashi K and Toyota T:
Inhibitory effect of troglitazone on diabetic neuropathy in
streptozotocin-induced diabetic rats. Diabetologia. 41:1321–1326.
1998.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Yamagishi S, Ogasawara S, Mizukami H,
Yajima N, Wada R, Sugawara A and Yagihashi S: Correction of protein
kinase C activity and macrophage migration in peripheral nerve by
pioglitazone, proliferator activated-gamma-ligand, in
insulin-deficient diabetic rats. J Neurochem. 104:491–499.
2008.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Wiggin TD, Kretzler M, Pennathur S,
Sullivan KA, Brosius FC and Feldman EL: Rosiglitazone treatment
reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice.
Endocrinology. 149:4928–4937. 2008.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Nabrdalik-Leśniak D, Nabrdalik K,
Sedlaczek K, Główczyński P, Kwiendacz H, Sawczyn T, Hajzler W,
Drożdż K, Hendel M, Irlik K, et al: Influence of SGLT2 inhibitor
treatment on urine antioxidant status in type 2 diabetic patients:
A pilot study. Oxid Med Cell Longev. 2021(5593589)2021.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Kandeel M: The outcomes of sodium-glucose
co-transporter 2 inhibitors (SGLT2I) on diabetes-associated
neuropathy: A systematic review and meta-analysis. Front Pharmacol.
13(926717)2022.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Ishibashi F, Kosaka A and Tavakoli M:
Sodium glucose cotransporter-2 inhibitor protects against diabetic
neuropathy and nephropathy in modestly controlled type 2 diabetes:
Follow-up study. Front Endocrinol (Lausanne).
13(864332)2022.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Wang C, Pan H, Wang W and Xu A: Effect of
dapagliflozin combined with mecobalamin on blood glucose
concentration and serum MDA, SOD, and COX-2 in patients with type 2
diabetes mellitus complicated with peripheral neuropathy. Acta
medica Mediterr. 35:2211–2215. 2019.
|
|
78
|
Bray JJH, Foster-Davies H, Salem A, Hoole
AL, Obaid DR, Halcox JPJ and Stephens JW: Glucagon-like peptide-1
receptor agonists improve biomarkers of inflammation and oxidative
stress: A systematic review and meta-analysis of randomised
controlled trials. Diabetes, Obes Metab. 23:1806–1822.
2021.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Oh Y and Jun HS: Effects of glucagon-like
peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci.
19(26)2017.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Ma J, Shi M, Zhang X, Liu X, Chen J, Zhang
R, Wang X and Zhang H: GLP-1R agonists ameliorate peripheral nerve
dysfunction and inflammation via p38 MAPK/NF-κB signaling pathways
in streptozotocin-induced diabetic rats. Int J Mol Med.
41:2977–2985. 2018.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Moustafa PE, Abdelkader NF, El Awdan SA,
El-Shabrawy OA and Zaki HF: Liraglutide ameliorated peripheral
neuropathy in diabetic rats: Involvement of oxidative stress,
inflammation and extracellular matrix remodeling. J Neurochem.
146:173–185. 2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Mohiuddin MS, Himeno T, Inoue R,
Miura-Yura E, Yamada Y, Nakai-Shimoda H, Asano S, Kato M, Motegi M,
Kondo M, et al: Glucagon-like peptide-1 receptor agonist protects
dorsal root ganglion neurons against oxidative insult. J Diabetes
Res. 2019(9426014)2019.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Brock C, Hansen CS, Karmisholt J, Møller
HJ, Juhl A, Farmer AD, Drewes AM, Riahi S, Lervang HH, Jakobsen PE
and Brock B: Liraglutide treatment reduced interleukin-6 in adults
with type 1 diabetes but did not improve established autonomic or
polyneuropathy. Br J Clin Pharmacol. 85:2512–2523. 2019.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Jaiswal M, Martin CL, Brown MB, Callaghan
B, Albers JW, Feldman EL and Pop-Busui R: Effects of exenatide on
measures of diabetic neuropathy in subjects with type 2 diabetes:
Results from an 18-month proof-of-concept open-label randomized
study. J Diabetes Complications. 29:1287–1294. 2015.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Ponirakis G, Abdul-Ghani MA, Jayyousi A,
Almuhannadi H, Petropoulos IN, Khan A, Gad H, Migahid O, Megahed A,
DeFronzo R, et al: Effect of treatment with exenatide and
pioglitazone or basal-bolus insulin on diabetic neuropathy: A
substudy of the Qatar study. BMJ Open Diabetes Res Care.
8(e001420)2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Saini K, Sharma S and Khan Y: DPP-4
inhibitors for treating T2DM-hype or hope? An analysis based on the
current literature. Front Mol Biosci. 10(1130625)2023.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Bolevich S, Milosavljevic I, Draginic N,
Andjic M, Jeremic N, Bolevich S, Litvitskiy PF and Jakovljevic V:
The effect of the chronic administration of dpp4-inhibitors on
systemic oxidative stress in rats with diabetes type 2. Serbian J
Exp Clin Res. 20:199–206. 2019.
|
|
88
|
Choi SW and Ho CK-C: Antioxidant
properties of drugs used in type 2 diabetes management. In:
Diabetes. 2nd Edition. Academic Press, pp139-148, 2020.
|
|
89
|
Nakashima S, Matsui T, Takeuchi M and
Yamagishi SI: Linagliptin blocks renal damage in type 1 diabetic
rats by suppressing advanced glycation end products-receptor axis.
Horm Metab Res. 46:717–721. 2014.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Zhang L, Li P, Tang Z, Dou Q and Feng B:
Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor
vildagliptin on the bone metabolism in ApoE-/- mice. Ann
Transl Med. 7(369)2019.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Kuthati Y, Rao VN, Busa P and Wong CS:
Teneligliptin exerts antinociceptive effects in rat model of
partial sciatic nerve transection induced neuropathic pain.
Antioxidants (Basel). 10(1438)2021.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Busa P, Kuthati Y, Huang N and Wong CS:
New advances on pathophysiology of diabetes neuropathy and pain
management: Potential role of melatonin and DPP-4 inhibitors. Front
Pharmacol. 13(864088)2022.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Tsuboi K, Mizukami H, Inaba W, Baba M and
Yagihashi S: The dipeptidyl peptidase IV inhibitor vildagliptin
suppresses development of neuropathy in diabetic rodents: Effects
on peripheral sensory nerve function, structure and molecular
changes. J Neurochem. 136:859–870. 2016.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Shrivastava A, Chaturvedi U, Singh SV,
Saxena JK and Bhatia G: Lipid lowering and antioxidant effect of
miglitol in triton treated hyperlipidemic and high fat diet induced
obese rats. Lipids. 48:597–607. 2013.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Sharma AK, Sharma A, Kumari R, Kishore K,
Sharma D, Srinivasan BP, Sharma A, Singh SK, Gaur S, Jatav VS, et
al: Sitagliptin, sitagliptin and metformin, or sitagliptin and
amitriptyline attenuate streptozotocin-nicotinamide induced
diabetic neuropathy in rats. J Biomed Res. 26:200–210.
2012.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Pecikoza U, Tomić M, Nastić K, Micov A and
Stepanović-Petrović R: Synergism between metformin and
analgesics/vitamin B12 in a model of painful diabetic
neuropathy. Biomed Pharmacother. 153(113441)2022.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Pop-Busui R, Lu J, Lopes N and Jones TLZ:
BARI 2D Investigators. Prevalence of diabetic peripheral neuropathy
and relation to glycemic control therapies at baseline in the BARI
2D cohort. J Peripher Nerv Syst. 14:1–13. 2009.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Singh R, Farooq SA, Mannan A, Singh TG,
Najda A, Grażyna Z, Albadrani GM, Sayed AA and Abdel-Daim MM:
Animal models of diabetic microvascular complications: Relevance to
clinical features. Biomed Pharmacother. 145(112305)2022.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Ahmad AA, Barani SSI and Sultan SJ: Role
of the IL-10 gene and its genetic variations in the development of
diabetes mellitus in women. World Acad Sci J. 7:1–7. 2025.
|
|
100
|
Singh M, Kapoor A and Bhatnagar A:
Physiological and pathological roles of aldose reductase.
Metabolites. 11(655)2021.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Mohammad RA, Saeed MK and Ali WK:
Evaluation of sorbitol dehydrogenase and some biochemical
parameters in patients with hepatitis. Kirkuk Univ J Sci Stud.
14:21–32. 2019.
|
|
102
|
Chiaradonna F, Ricciardiello F and
Palorini R: The nutrient-sensing hexosamine biosynthetic pathway as
the hub of cancer metabolic rewiring. Cells. 7(53)2018.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Mustafa YF: Harmful free radicals in
aging: A narrative review of their detrimental effects on health.
Indian J Clin Biochem. 39:154–167. 2024.PubMed/NCBI View Article : Google Scholar
|
